you are viewing a single comment's thread.
The following link is to an article that presents a good overview of the current treatment options in development for HCC. http://www.springerlink.com/content/d84x879816568502/fulltext.pdfIt has the standard RECIST ORR for the full Brevanib phase 2 trial and it isn't very impressive. The reported 184 rate was 3/16. We will see if the R&D day presentation updates that statistic.